EA202091964A1 - КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ - Google Patents

КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ

Info

Publication number
EA202091964A1
EA202091964A1 EA202091964A EA202091964A EA202091964A1 EA 202091964 A1 EA202091964 A1 EA 202091964A1 EA 202091964 A EA202091964 A EA 202091964A EA 202091964 A EA202091964 A EA 202091964A EA 202091964 A1 EA202091964 A1 EA 202091964A1
Authority
EA
Eurasian Patent Office
Prior art keywords
inhibitor
bcl
diseases
prevention
treatment
Prior art date
Application number
EA202091964A
Other languages
English (en)
Inventor
Дацзюнь Ян
Ифань Чжай
Цюцюн Тан
Дуглас Дун Фан
Original Assignee
Эсентейдж Фарма (Сучжоу) Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эсентейдж Фарма (Сучжоу) Ко., Лтд. filed Critical Эсентейдж Фарма (Сучжоу) Ко., Лтд.
Publication of EA202091964A1 publication Critical patent/EA202091964A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

В данном документе предусматривается комбинированный продукт, содержащий ингибитор Bcl-2 и ингибитор MDM2, при этом комбинированный продукт предусматривает применение в предупреждении и/или лечении заболеваний (например, рака).
EA202091964A 2018-07-31 2019-07-22 КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ EA202091964A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810862170 2018-07-31
PCT/CN2019/096968 WO2020024820A1 (en) 2018-07-31 2019-07-22 Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases

Publications (1)

Publication Number Publication Date
EA202091964A1 true EA202091964A1 (ru) 2021-05-13

Family

ID=69232313

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091964A EA202091964A1 (ru) 2018-07-31 2019-07-22 КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ

Country Status (14)

Country Link
US (1) US11478469B2 (ru)
EP (1) EP3672594B1 (ru)
JP (1) JP7058345B2 (ru)
KR (1) KR20210003731A (ru)
CN (1) CN110772639B (ru)
AU (1) AU2019314624B2 (ru)
BR (1) BR112020018978A2 (ru)
CA (1) CA3094449C (ru)
EA (1) EA202091964A1 (ru)
GE (1) GEP20237458B (ru)
MX (1) MX2020009757A (ru)
TW (1) TWI752335B (ru)
UA (1) UA126098C2 (ru)
WO (1) WO2020024820A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020009759A (es) 2018-07-31 2020-10-08 Ascentage Pharma Suzhou Co Ltd Efecto antitumoral sinergico de un inhibidor de bcl-2 combinado con rituximab y/o bendamustina o un inhibidor de bcl-2 combinado con chop.
AU2019314819A1 (en) 2018-07-31 2020-10-22 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
AU2019314624B2 (en) 2018-07-31 2022-03-03 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
AU2020323033A1 (en) * 2019-07-26 2021-04-22 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease
TWI772992B (zh) * 2019-12-03 2022-08-01 大陸商蘇州亞盛藥業有限公司 作為bcl-2抑制劑的n-(苯基磺醯基)苯甲醯胺及相關化合物
EP4069233A4 (en) * 2019-12-04 2024-03-13 Ascentage Pharma (Suzhou) Co., Ltd. PHARMACEUTICAL COMBINATION AND USE THEREOF
CN113337602A (zh) * 2020-03-02 2021-09-03 苏州亚盛药业有限公司 Mdm2抑制剂的治疗方法和生物标志物
CN113354636B (zh) * 2020-03-06 2022-08-09 苏州亚盛药业有限公司 N-(苯基磺酰基)苯甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
CN113521064A (zh) * 2020-04-14 2021-10-22 苏州亚盛药业有限公司 Mdm2抑制剂的新用途
WO2022111558A1 (en) * 2020-11-25 2022-06-02 Ascentage Pharma (Suzhou) Co., Ltd. Solid dispersion, pharmaceutical preparations, preparation method, and application thereof
WO2022143602A1 (en) * 2020-12-28 2022-07-07 Ascentage Pharma (Suzhou) Co., Ltd. Methods of treating multiple sclerosis
EP4382126A1 (en) * 2021-08-02 2024-06-12 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical combination and use thereof
EP4398905A1 (en) * 2021-09-09 2024-07-17 Kartos Therapeutics Methods of treating a cancer overexpressing one or more bcl-2 family proteins

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
US7842681B2 (en) 2006-09-05 2010-11-30 Abbott Laboratories Treatment of myeoproliferative diseases
RU2009125575A (ru) 2006-12-04 2011-01-20 Эбботт Лэборетриз (Us) Комплексные диагностические анализы для терапии рака
JP2011522773A (ja) 2007-12-27 2011-08-04 インフィニティ ファーマスーティカルズ、インク． 治療剤での癌の処置方法
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
EP2376480B1 (en) 2008-12-05 2016-06-01 AbbVie Inc. Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
WO2010093742A1 (en) 2009-02-11 2010-08-19 Abbott Laboratories Methods and compositions for identifying, classifying and monitoring subject having bcl-2 family inhibitor-resistant tumors and cancers
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101920202B1 (ko) 2009-05-26 2018-11-21 애브비 아일랜드 언리미티드 컴퍼니 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
RU2598345C2 (ru) 2010-10-29 2016-09-20 Эббви Инк. Твердые дисперсии, содержащие средства, вызывающие апоптоз
PT2642999T (pt) 2010-11-23 2017-01-05 Abbvie Ireland Unlimited Co Métodos de tratamento que utilizam inibidores seletivos de bcl-2
BR112013012740A2 (pt) 2010-11-23 2016-09-13 Abbvie Inc sais e formas cristalinas de um agente que induz apoptose
EP2668180B1 (en) 2011-01-25 2018-08-01 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
SG11201505525UA (en) 2013-01-16 2015-08-28 Univ Michigan Bcl-2bcl-xl inhibitors and therapeutic methods using the same
ES2818110T3 (es) 2014-02-28 2021-04-09 Merck Sharp & Dohme Tratamiento del cáncer con una combinación que comprende dinaciclib
AU2015247646B2 (en) * 2014-04-17 2019-06-06 The Regents Of The University Of Michigan MDM2 inhibitors and therapeutic methods using the same
HRP20211813T1 (hr) 2014-08-11 2022-03-04 Acerta Pharma B.V. Terapeutske kombinacije inhibitora btk i inhibitora bcl-2
CN105061315B (zh) * 2015-08-06 2017-10-24 大连理工大学 一类1,5‑二苯基吡唑‑3‑羧酸类化合物及其应用
RU2020142739A (ru) * 2015-08-28 2021-01-15 Новартис Аг Ингибиторы mdm2 и их комбинации
BR112019001666A2 (pt) * 2016-08-05 2019-05-28 Univ Michigan Regents n-(fenilsulfonil)benzamidas e compostos relacionados como inibidores de bcl-2
AU2019314624B2 (en) 2018-07-31 2022-03-03 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and MDM2 inhibitor and use thereof in the prevention and/or treatment of diseases
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
MX2020009759A (es) 2018-07-31 2020-10-08 Ascentage Pharma Suzhou Co Ltd Efecto antitumoral sinergico de un inhibidor de bcl-2 combinado con rituximab y/o bendamustina o un inhibidor de bcl-2 combinado con chop.
AU2019314819A1 (en) 2018-07-31 2020-10-22 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
EP3706741A4 (en) 2018-11-23 2022-03-30 Ascentage Pharma (Suzhou) Co., Ltd. PHARMACEUTICAL COMPOSITION AND USE THEREOF

Also Published As

Publication number Publication date
JP2021525224A (ja) 2021-09-24
EP3672594A1 (en) 2020-07-01
TW202019407A (zh) 2020-06-01
CA3094449C (en) 2023-02-28
BR112020018978A2 (pt) 2021-03-02
MX2020009757A (es) 2020-10-08
WO2020024820A1 (en) 2020-02-06
TWI752335B (zh) 2022-01-11
EP3672594A4 (en) 2020-11-25
AU2019314624B2 (en) 2022-03-03
JP7058345B2 (ja) 2022-04-21
CN110772639B (zh) 2021-04-13
AU2019314624A1 (en) 2020-10-01
GEP20237458B (en) 2023-01-10
UA126098C2 (uk) 2022-08-10
US11478469B2 (en) 2022-10-25
KR20210003731A (ko) 2021-01-12
CA3094449A1 (en) 2020-02-06
CN110772639A (zh) 2020-02-11
EP3672594B1 (en) 2021-09-29
US20220031694A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
EA202091964A1 (ru) КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 И ИНГИБИТОРА MDM2 И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
EA202091965A1 (ru) КОМБИНИРОВАННЫЙ ПРОДУКТ НА ОСНОВЕ ИНГИБИТОРА Bcl-2 ИЛИ ДВОЙНОГО ИНГИБИТОРА Bcl-2/Bcl-xL И ИНГИБИТОРА BTK И ЕГО ПРИМЕНЕНИЕ В ПРЕДУПРЕЖДЕНИИ И/ИЛИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
PH12021550152A1 (en) Anti-cd112r compositions and methods
EA202092000A1 (ru) Ингибиторы димеризации egfr и их использование
EA202091615A1 (ru) Интраназальные составы на основе эпинефрина и способы лечения заболевания
EA201890428A1 (ru) Ингибиторы контрольных точек иммунного ответа для применения в лечении различных видов рака крови
GEP20227443B (en) Magl inhibitors
MX2023002507A (es) Inhibidores de cd73.
MX2021003187A (es) Inhibición de la peptidasa específica de ubiquitina 9x.
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
EA201791736A1 (ru) Комбинированная терапия для лечения рака
PH12020551716A1 (en) Anti-ror antibody constructs
MX2022005123A (es) Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MX2020008122A (es) Anticuerpos anti-pd-1.
CY1124123T1 (el) Φαρμακευτικοι συνδυασμοι για θεραπεια καρκινου
BR112022008365A2 (pt) Inibidores de cd73
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
MX2022006312A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
GEP20217301B (en) Combination of bcl-2 inhibitor and mcl-1 inhibitor, uses and pharmaceutical compositions thereof
MX2020008969A (es) Tratamiento y prevencion de preeclampsia.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.